The UK pharma industry has responded to proposed changes to the statutory scheme for branded medicines, arguing against their implementation.
The Association of the British Pharmaceutical Industry (ABPI) said the changes, made as the UK negotiates a new drug pricing framework with the industry, would likely deter investment in R&D, limiting access to clinical trials.
The statutory scheme is a default rebate mechanism in the UK, defining a percentage on sales which must be repaid to the British government.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze